RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+25.68%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.77B
AUM Growth
+$6.77B
(+5.8%)
Cap. Flow
-$132M
Cap. Flow
% of AUM
-1.95%
Top 10 Holdings %
Top 10 Hldgs %
45.13%
Holding
79
New
15
Increased
25
Reduced
7
Closed
10
Top Buys
| 1 |
Stryker
SYK
|
$115M |
| 2 |
Immatics
IMTX
|
$89.5M |
| 3 |
Dyne Therapeutics
DYN
|
$87.8M |
| 4 |
Merus
MRUS
|
$78.2M |
| 5 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$72.8M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$398M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$314M |
| 3 |
Celldex Therapeutics
CLDX
|
$137M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$112M |
| 5 |
Vericel Corp
VCEL
|
$83.6M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
26
DELISTED
Sage Therapeutics
SAGE
| $103M | 1.52% |
5,480,577
+283,558
| +5% | +$5.31M |
|
|
SWAV
27
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $94M | 1.39% |
288,684
+223,624
| +344% | +$72.8M |
|
|
28
Dyne Therapeutics
DYN
$1.92B
| $87.8M | 1.3% |
+3,091,587
| New | +$87.8M |
|
29
89bio
ETNB
$1.37B
| $85.9M | 1.27% |
7,378,548
+1,799,617
| +32% | +$20.9M |
|
30
Spyre Therapeutics
SYRE
$1.02B
| $84.7M | 1.25% |
2,232,760
| – | – |
|
|
31
Vericel Corp
VCEL
$1.69B
| $83.6M | 1.23% |
1,606,397
-1,606,397
| -50% | -$83.6M |
|
|
CRGX
32
DELISTED
CARGO Therapeutics
CRGX
| $83.4M | 1.23% |
3,735,619
-1,440,213
| -28% | -$32.1M |
|
33
RadNet
RDNT
$5.46B
| $82.7M | 1.22% |
1,700,550
+1,036,948
| +156% | +$50.5M |
|
34
Thermo Fisher Scientific
TMO
$183B
| $64.2M | 0.95% |
110,500
+60,500
| +121% | +$35.2M |
|
35
10x Genomics
TXG
$1.66B
| $58.4M | 0.86% |
1,554,856
+4,905
| +0.3% | +$184K |
|
36
Stoke Therapeutics
STOK
$1.08B
| $57M | 0.84% |
4,224,838
+93,793
| +2% | +$1.27M |
|
37
Fulcrum Therapeutics
FULC
$353M
| $55.2M | 0.81% |
5,845,956
+376,000
| +7% | +$3.55M |
|
38
Taysha Gene Therapies
TSHA
$791M
| $53.4M | 0.79% |
18,593,185
+1,700,000
| +10% | +$4.88M |
|
39
Insmed
INSM
$30.3B
| $50.6M | 0.75% |
1,865,108
| – | – |
|
40
UroGen Pharma
URGN
$896M
| $48.9M | 0.72% |
3,257,347
+1,530,539
| +89% | +$23M |
|
41
Kyverna Therapeutics
KYTX
$161M
| $46M | 0.68% |
+1,852,711
| New | +$46M |
|
42
Intuitive Surgical
ISRG
$158B
| $39.5M | 0.58% |
+99,000
| New | +$39.5M |
|
43
Neurogene
NGNE
$284M
| $39.1M | 0.58% |
+769,122
| New | +$39.1M |
|
44
Janux Therapeutics
JANX
$1.38B
| $37.7M | 0.56% |
+1,000,000
| New | +$37.7M |
|
45
GH Research
GHRS
$870M
| $35.5M | 0.52% |
3,327,129
| – | – |
|
46
Orchestra BioMed
OBIO
$147M
| $29.6M | 0.44% |
5,620,640
| – | – |
|
47
Dianthus Therapeutics
DNTH
$781M
| $20M | 0.3% |
+666,667
| New | +$20M |
|
48
ESSA Pharma
EPIX
$11.2M
| $19.5M | 0.29% |
2,298,662
| – | – |
|
|
LENZ
49
LENZ Therapeutics
LENZ
$1.12B
| $19.3M | 0.28% |
+863,389
| New | +$19.3M |
|
50
CG Oncology
CGON
$2.19B
| $18.2M | 0.27% |
+413,670
| New | +$18.2M |
|